NCT05908006 is a clinical trial of Velacur in Non-alcoholic Fatty Liver Disease (NAFLD), sponsored by GI Alliance.

Who is sponsoring NCT05908006?

NCT05908006 is sponsored by GI Alliance.

What drugs are being tested in NCT05908006?

Interventions in NCT05908006: Velacur.

What condition does NCT05908006 study?

NCT05908006 studies Non-alcoholic Fatty Liver Disease (NAFLD).

Is NCT05908006 still recruiting?

NCT05908006 is currently status unknown. Last updated 18 June 2023.

Last reviewed 2023-06-18 · How we verify

NCT05908006

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Validation Study of the Velacur System in Comparison to MRE & MRI-PDFF in Patients With (Suspected) Liver Disease

Status unknown Last updated 18 June 2023

What this trial tests

trial testing Velacur in Non-alcoholic Fatty Liver Disease (NAFLD) in 100 participants. Status unknown.

Timeline

15 July 2023

Primary endpoint
30 December 2023

31 January 2024

Quick facts

Lead sponsor	GI Alliance
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	15 July 2023
Primary completion	30 December 2023
Estimated completion	31 January 2024
Sites	2 locations across United States

Drugs / interventions tested

Velacur

Conditions studied

Non-alcoholic Fatty Liver Disease (NAFLD) — all drugs for Non-alcoholic Fatty Liver Disease (NAFLD) →

Sponsor

GI Alliance

Who can join

Adults 18 to 80, any sex, with Non-alcoholic Fatty Liver Disease (NAFLD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this open-label, non-randomized, prospective study is to compare Velacur and MRE in all sexes, 18-80 years old with Non-Alcoholic Fatty Liver Disease (NAFLD). The main aims is to: * Validate the use of Velacur and elastography cut offs in a patient cohort with all types of chronic liver disease, against MRE results for fibrosis staging. * Validate the use of Velacur and attenuation cut offs in a patient cohort with all types of chronic liver disease, against MRI-PDFF results for steatosis staging. Participants will Study participants will attend 1 study visit, in which measurement of liver stiffness with Velacur and FibroScan, will be performed by a certified technician. As part of Visit 1, Patients will also complete an MRI exam which will include both MRE and MRI-PDFF measurements (MRI imaging can take place within 28 days of the Velacur scan).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Validation of Velacur Liver Stiffness and Attenuation in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
Surapaneni SN, Hogan R, Mury T, Horton A, et al · · 2026 · PMID 42205166 · DOI 10.1016/j.gastha.2026.100952

Verify or expand the search:

Other trials of Velacur

Trials testing the same drug.

NCT04576897 — Velacur by Sonic Incytes for Portal Hypertension · NA · completed

Other recruiting trials for Non-alcoholic Fatty Liver Disease (NAFLD)

Currently open trials in the same condition.

NCT07172997 — Non-Invasive MASLD Diagnosis & T2D Remission Biomarkers · active not recruiting
NCT06913699 — The Ameliorative Effect of C-Kit (+) Hepatic Endothelial Cells With Mertk Deficiency on Nonalcoholic Steatohepatitis · active not recruiting
NCT05384652 — Simultaneous Quantification of Liver Fat Content, Fatty Acid Composition, and Fibrosis Using Spin-lock MRI for Steatohep · active not recruiting
NCT05699018 — Screening in Primary Care of Advanced Liver Fibrosis in NAFLD And/or Alcoholic Patients · NA · recruiting
NCT04820036 — A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG) · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05908006 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GI Alliance
Last refreshed: 18 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05908006.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing